YN440294 Tyrphostin AG1296 146535-11-7

Tyrphostin AG 1296 is an inhibitor of PDGFR with IC50 of 0.3-0.5 μM, no activity to EGFR.

YN440104 Telatinib 332012-40-5

Telatinib is a potent inhibitor of VEGFR2/3, c-Kit and PDGFRα with IC50 of 6 nM/4 nM, 1 nM and 15 nM, respectively. Phase 2.

YN440077 Toceranib 356068-94-5

Toceranib phosphate (SU11654 phosphate) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits PDGFR,VEGFR, and Kitwith Kis of 5 and 6nM for PDGFRβ and Flk-1/KDR, respectiv...

YN440056 Tandutinib 387867-13-2

Tandutinib (MLN518, CT53518) is a potent FLT3 antagonist with IC50 of 0.22 μM, also inhibits PDGFR and c-Kit, 15 to 20-fold higher potency for FLT3 versus CSF-1R and >100-fold selectivity for the same target versus...

YN440410 Dovitinib 405169-16-6

Dovitinib (TKI258, CHIR258) is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit) with IC50 of 1 nM/2 nM, also potent to class IV (FGFR1/3) and class V (VEGFR1-4) RTKs with IC50 of 8-13 n...

YN440128 Lenvatinib 417716-92-8

Lenvatinib (E7080) is a multi-target inhibitor, mostly for VEGFR2(KDR)/VEGFR3(Flt-4) with IC50 of 4 nM/5.2 nM, less potent against VEGFR1/Flt-1, ~10-fold more selective for VEGFR2/3 against FGFR1, PDGF...

YN440062 Pazopanib 444731-52-6

Pazopanib is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.

YN440065 Motesanib 453562-69-1

Motesanib (AMG-706) is an orally bioavailable receptor tyrosine kinase inhibitor with IC50 values of 2 nM, 3 nM, 6 nM, 8 nM, 84 nM, 59 nM for VEGFR1, VEGFR2, VEGFR3, Kit, PDGFR and Ret, respectively.

YN440100 SU14813 627908-92-3

SU14813 is a multi-targeted receptor tyrosine kinases inhibitor with IC50s of 50, 2, 4, 15nM forVEGFR2,VEGFR1,PDGFRβ and KIT.

YN440061 Dovitinib lactate 692737-80-7

Dovitinib lactate (TKI258 lactate) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210nM forFLT3,c-Kit,FGFR1/3,VEGFR1/2/3 and PDGFRα/β, respectively.

YN440063 Masitinib 790299-79-5

Masitinib is a novel inhibitor for Kit and PDGFRα/β with IC50 of 200 nM and 540 nM/800 nM, weak inhibition to ABL and c-Fms. Phase 3.

YN440239 Cabozantinib 849217-68-1

Cabozantinib (XL184, BMS-907351) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM an...

YN440101 SU14813 maleate 849643-15-8

SU14813 maleate is a multi-targeted receptor tyrosine kinases inhibitor with IC50s of 50, 2, 4, 15nM forVEGFR2,VEGFR1,PDGFRβ and KIT.

YN440060 Amuvatinib 850879-09-3

Amuvatinib (MP-470) is a potent and multi-targeted inhibitor of c-Kit, PDGFRα and Flt3 with IC50 of 10 nM, 40 nM and 81 nM, respectively. Phase 2.

YN440066 Motesanib Diphosphate 857876-30-3

Motesanib Diphosphate (AMG-706) is a potent ATP-competitive inhibitor of VEGFR1/2/3 with IC50 of 2 nM/3 nM/6 nM, respectively similar activity against Kit, ~10-fold more selective for VEGFR than PDGFR and Ret. ...

YN440129 Lenvatinib mesylate 857890-39-2

Lenvatinib Mesylate is a synthetic, orally available inhibitor of VEGFR2 tyrosine kinase with potential antineoplastic activity.

YN440078 Toceranib phosphate 874819-74-6

Toceranib phosphate is a multitargeted indolinone receptor tyrosine kinase (RTK) inhibitor with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively.

YN440374 AZD2932 883986-34-3

AZD2932 is a potent and mutil-targeted protein tyrosine kinase inhibitor with IC50 of 8 nM, 4 nM, 7 nM, and 9 nM for VEGFR-2, PDGFRβ, Flt-3, and c-Kit, respectively.

YN440030 ISCK03 945526-43-2

ISCK03 is a specificSCF/c-Kitinhibitor.

YN440064 Masitinib mesylate 1048007-93-7

Masitinib mesylate (AB-1010 mesylate) is a potent, orally bioavailable, and selective inhibitor ofc-Kit(IC50=200nM for human recombinant c-Kit). It also inhibits PDGFRα/β(IC50s=540/800nM),Lyn(IC50= 510nM for LynB)...